Skip to main content

 Scientific publications

Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer.

Authors : Mierzynska J, Taye M, Pe M, Coens C, Martinelli F, Pogoda K, Velikova G, Bjelic-Radisic V, Cardoso F, Brain E, Ignatiadis M, Piccart-Gebhart M, Van Tienhoven G, Mansel R, Wildiers H, Bottomley A
Year : 2020
Journal : Eur J Cancer
Volume : 125
Pages : 69-82

Post-Mastectomy Radiation Therapy in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer Patients: Analysis of the HERA Trial.

Authors : Abi Jaoude J, de Azambuja E, Makki M, Tamim H, Tfayli A, Geara F, Piccart-Gebhart M, Poortmans P, Zeidan YH
Year : 2020
Journal : Int J Radiat Oncol Biol Phys
Volume : 106
Pages : 503-510

A pooled analysis of the cardiac events in the trastuzumab adjuvant trials.

Authors : de Azambuja E, Ponde N, Procter M, Rastogi P, Cecchini RS, Lambertini M, Ballman K, Aspitia AM, Zardavas D, Roca L, Gelber Rd, Piccart-Gebhart M, Suter T
Year : 2020
Journal : Breast Cancer Res Treat
Volume : 179
Pages : 161-171

Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial.

Authors : Delaloge S, Piccart-Gebhart M, Rutgers E, Litière S, van t Veer LJ, van den Berkmortel F, Brain E, Dudek-Peric A, Gil-Gil M, Gomez P, Hilbers FS, Khalil Z, Knox S, Kuemmel S, Kunz G, Lesur A, Pierga JY, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Thompson AM, Viale G, Zoppoli G, Vuylsteke P, Tryfonidis K, Poncet C, Bogaerts J, Cardoso F
Year : 2020
Journal : J Clin Oncol
Pages : JCO1901371

Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy.

Authors : Di Cosimo S, Appierto V, Pizzamiglio S, Silvestri M, Baselga J, Piccart-Gebhart M, Huober J, Izquierdo M, de la Pena L, Hilbers FS, de Azambuja E, Untch M, Pusztai L, Pritchard K, Nuciforo P, Vincent-Salomon A, Symmans F, Apolone G, De Braud FG, Iorio MV, Verderio P, Daidone MG
Year : 2020
Journal : Int J Mol Sci
Volume : 21

What is the real impact of estrogen receptor status on the prognosis and treatment of HER2-positive early breast cancer?

Authors : Brandão M, Caparica R, Malorni L, Prat A, Carey LA, Piccart-Gebhart M
Year : 2020
Journal : Clin Cancer Res

International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium.

Authors : Coens C, Pe M, Dueck AC, Sloan J, Basch E, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Devlin N, Dorme L, Flechtner HH, Gotay C, Griebsch I, Groenvold M, King M, Kluetz PG, Koller M, Malone DC, Martinelli F, Mitchell SA, Musoro JZ, OConnor D, Oliver K, Piault-Louis E, Piccart-Gebhart M, Quinten C, Reijneveld JC, Schürmann C, Smith AW, Soltys KM, Taphoorn MJB, Velikova G, Bottomley A
Year : 2020
Journal : Lancet Oncol
Volume : 21
Pages : e83-e96

Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer.

Authors : Pondé N, Amaye L, Lambertini M, Paesmans M, Piccart-Gebhart M, de Azambuja E
Year : 2020
Journal : Eur J Cancer
Volume : 126
Pages : 65-73

Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Authors : Bines J, Procter M, Restuccia E, Viale G, Zardavas D, Suter T, Arahmani A, van Dooren V, Baselga J, Clark E, Eng-Wong J, Gelber Rd, Piccart-Gebhart M, Mobus V, de Azambuja E
Year : 2020
Journal : Clin Breast Cancer
Volume : 20
Pages : 174-181.e3

Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors.

Authors : Franzoi MA, Vandeputte C, Eiger D, Caparica R, Brandão M, de Angelis C, Hendlisz A, Awada A, Piccart-Gebhart M, de Azambuja E
Year : 2020
Journal : Breast Cancer Res Treat

Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial.

Authors : Eiger D, Pondé NF, Agbor-Tarh D, Moreno-Aspitia A, Piccart-Gebhart M, Hilbers FS, Werner O, Chumsri S, Dueck A, Kroep JR, Gomez H, Láng I, Rodeheffer RJ, Ewer MS, Suter T, de Azambuja E
Year : 2020
Journal : Br J Cancer

The Legacy of Professor Aron Goldhirsch.

Authors : Gelber Rd, Coates AS, Gelber S, Orecchia R, Veronesi P, Di Leo A, Colleoni M, Winer EP, Burstein HJ, Viale G, Senn HJ, Piccart-Gebhart M, Curigliano G
Year : 2020
Journal : Ann Oncol

Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients.

Authors : Lambertini M, Campbell C, Bines J, Korde LA, Izquierdo M, Fumagalli D, Del Mastro L, Ignatiadis M, Pritchard K, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Barrios CH, Baselga J, Moreno-Aspitia A, Piccart-Gebhart M, Gelber Rd, de Azambuja E
Year : 2019
Journal : J Natl Cancer Inst
Volume : 111
Pages : 86-94

Corrections to PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab"."

Authors : Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart-Gebhart M, Von Minckwitz G, Baselga J
Year : 2019
Journal : Ann Oncol
Volume : 30
Pages : 1180

Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019.

Authors : Burstein HJ, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P, Colleoni M, Denkert C, Piccart-Gebhart M, Regan M, Senn HJ, Winer EP, Thurlimann B
Year : 2019
Journal : Ann Oncol
Volume : 30
Pages : 1541-1557

Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial.

Authors : Holmes EM, Bradbury I, Williams LS, Korde L, de Azambuja E, Fumagalli D, Moreno-Aspitia A, Baselga J, Piccart-Gebhart M, Dueck AC, Gelber Rd
Year : 2019
Journal : Ann Oncol
Volume : 30
Pages : 1507-1513

ESR1 mutations in metastatic lobular breast cancer patients.

Authors : Desmedt C, Pingitore J, Rothé F, Marchio C, Clatot F, Rouas G, Richard F, Bertucci F, Mariani O, Galant C, Fribbens C, OLeary B, Van den Eynden G, Salgado R, Turner NC, Piccart-Gebhart M, Vincent-Salomon A, Pruneri G, Larsimont D, Sotiriou C
Year : 2019
Journal : NPJ Breast Cancer
Volume : 5
Pages : 9

Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives.

Authors : Caparica R, Lambertini M, Pondé N, Fumagalli D, de Azambuja E, Piccart-Gebhart M
Year : 2019
Journal : Ther Adv Med Oncol
Volume : 11
Pages : 1758835919827714

Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial.

Authors : Di Cosimo S, Appierto V, Pizzamiglio S, Tiberio P, Iorio MV, Hilbers F, de Azambuja E, de la Peña L, Izquierdo M, Huober J, Baselga J, Piccart-Gebhart M, De Braud FG, Apolone G, Verderio P, Daidone MG
Year : 2019
Journal : Clin Cancer Res
Volume : 25
Pages : 3887-3895

BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer.

Authors : Solinas C, Marcoux D, Garaud S, Vitória JR, Van den Eynden G, de Wind A, De Silva P, Boisson A, Craciun L, Larsimont D, Piccart-Gebhart M, Detours V, Tkint de Roodenbeke D, Willard-Gallo K
Year : 2019
Journal : Cancer Lett
Volume : 450
Pages : 88-97